SPDR S&P Biotech ETF $XBI Stake Lowered by Jaffetilchin Investment Partners LLC

Jaffetilchin Investment Partners LLC lowered its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 33.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 2,705 shares of the exchange traded fund’s stock after selling 1,366 shares during the period. Jaffetilchin Investment Partners LLC’s holdings in SPDR S&P Biotech ETF were worth $224,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in SPDR S&P Biotech ETF by 625.1% during the 1st quarter. JPMorgan Chase & Co. now owns 10,369,706 shares of the exchange traded fund’s stock valued at $840,983,000 after purchasing an additional 12,344,558 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of SPDR S&P Biotech ETF by 33.0% during the first quarter. Goldman Sachs Group Inc. now owns 13,524,858 shares of the exchange traded fund’s stock worth $1,096,866,000 after buying an additional 3,353,029 shares during the period. Simplex Trading LLC grew its holdings in SPDR S&P Biotech ETF by 116.1% in the 1st quarter. Simplex Trading LLC now owns 241,039 shares of the exchange traded fund’s stock worth $19,548,000 after buying an additional 1,741,445 shares in the last quarter. Meitav Investment House Ltd. increased its position in SPDR S&P Biotech ETF by 2,199.6% in the 2nd quarter. Meitav Investment House Ltd. now owns 400,454 shares of the exchange traded fund’s stock valued at $33,229,000 after acquiring an additional 383,040 shares during the period. Finally, Strs Ohio acquired a new stake in SPDR S&P Biotech ETF in the 1st quarter valued at approximately $27,801,000.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA:XBI opened at $121.37 on Wednesday. The stock has a market cap of $7.37 billion, a price-to-earnings ratio of 11.47 and a beta of 0.93. SPDR S&P Biotech ETF has a 1 year low of $66.66 and a 1 year high of $121.41. The business has a fifty day moving average of $107.30 and a 200-day moving average of $93.42.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.